Preventive Gynaecology Unit, European Institute of Oncology, via Ripamonti 435, Milan, Italy.
J Womens Health (Larchmt). 2011 Mar;20(3):397-402. doi: 10.1089/jwh.2010.2189. Epub 2011 Feb 25.
Human papillomavirus (HPV) testing can be used as a primary test for cervical cancer screening. HPV self-sampling has the potential to replace physician/nurse sampling. Our objective was to compare the acceptability of two self-sampling methods among 205 women undergoing an excisional procedure for cervical intraepithelial neoplasia (CIN) at the European Institute of Oncology (IEO).
One hundred eleven patients were given a Hybrid Capture (HC) Cervical Sampler™ (Qiagen, Hilden, Germany), and 94 received a self-lavaging device, the Delphi® Screener (Delphi Bioscience, Scherpenzeel, The Netherlands), both with written instructions. Self-sampling was performed just before the clinician-collected cervical sample. Women responded to questions using 5-point ordinal scales on the general acceptability of self-sampling and the physical comfort, embarrassment, pain, and difficulty experienced. Participants were also asked whether they prefer self-sampling or clinician sampling.
Both self-sampling methods were generally accepted with a significantly high score (p = 0.005) and significantly lower embarrassment (p = 0.042) in favor of the Delphi Screener. Both self-sampling methods were physically well accepted, not painful, and easy to perform. Most women (n = 117, 68%) preferred the self-sampled compared to the clinician-sampled test, with a significantly higher proportion in the Delphi Screener group (n = 59, 77.6%) compared to those using the HC Sampler (n = 58, 60.4%) (p = 0.021).
The present study shows that self-sampling for HPV testing is favorably received by women. A sampling device specifically developed for self-sampling, such as the Delphi Screener, shows the highest degree of satisfaction. A well-accepted HPV sampling method could be especially useful for women who do not take part in cervical screening or in settings where organized screening is not fully implemented.
人乳头瘤病毒(HPV)检测可用作宫颈癌筛查的初筛方法。HPV 自采样有可能替代医生/护士采样。我们的目的是比较两种自采样方法在欧洲肿瘤研究所(IEO)接受宫颈上皮内瘤变(CIN)切除术的 205 名女性中的接受程度。
111 名患者使用 Hybrid Capture(HC)Cervical Sampler™(Qiagen,德国 Hilden),94 名患者使用 Delphi®Screener(Delphi Bioscience,荷兰 Scherpenzeel),均附有书面说明。自采样在临床医生采集的宫颈样本之前进行。女性使用 5 分制有序量表对自采样的总体可接受性以及身体舒适度、尴尬感、疼痛和难度进行回答。参与者还被问及他们更喜欢自采样还是临床医生采样。
两种自采样方法均得到广泛认可,评分显著较高(p=0.005),且 Delphi Screener 组的尴尬感显著较低(p=0.042)。两种自采样方法均得到较好的身体接受,无痛且易于操作。大多数女性(n=117,68%)更喜欢自采样检测,而不是临床医生采样检测,使用 Delphi Screener 的女性比例显著高于使用 HC Sampler 的女性(n=59,77.6%比 n=58,60.4%)(p=0.021)。
本研究表明,HPV 检测的自采样方法受到女性的欢迎。专门为自采样开发的采样装置,如 Delphi Screener,显示出最高的满意度。一种广泛接受的 HPV 采样方法对于那些不参加宫颈癌筛查或组织筛查未完全实施的环境中的女性特别有用。